EUCTR2007-005995-14-AT进行中（未招募）不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E e4 Carriers
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA0 个研究点目标入组 1,100 人开始时间: 2008年5月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed and dated written informed consent obtained from the subject or the subject’s legally acceptable representative (if applicable) in accordance with the local regulations.
- •The subject’s caregiver must also consent to participate in the study.
- •2. Man or surgically sterile or postmenopausal woman, aged =50 to <89 years.
- •3. Diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria (Attachment 1).
- •4. MMSE score of 16 to 26, inclusive.
- •5. Rosen Modified Hachinski Ischemic Score =4.
- •6. Lives at home with appropriate caregiver capable of accompanying the subject on all clinic visits, or community dwelling with caregiver capable of accompanying the subject on all clinic visits and visiting with the subject approximately 5 times per week for the duration of the study.
- •7. Screening visit brain MRI scan consistent with the diagnosis of AD.
- •8. Fluency in local language and evidence of adequate premorbid intellectual functioning.
- •9. NOTE: With sponsor approval, subjects fluent in their native language may be included if appropriate staff at the intended site are also fluent in that language and if required study documents (e.g. rating assessments and informed consent form) are available in the native language of the subject.
- •10. Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
- •11. Receiving stable doses of medication(s) for the treatment of nonexcluded medical condition(s) for at least 30 days prior to screening, and, if treated with cholinesterase inhibitors and/or memantine, all of the following conditions are also met:
- •a. The subject is maintained on a stable dose regimen for at least 120 days prior to screening.
- •b. The subject is free of any clinically important side effects attributable to the drug.
- •c. The subject and caregiver agree that, barring unforeseen circumstances, they will continue the same regimen for the duration of the trial.
- •12. The subject and caregiver are likely to be able to participate in all scheduled evaluations and complete all required tests.
- •13. Willing to undergo apolipoprotein E (ApoE) genotype testing.
- •14. Carrier of ApoE4 according to genotyping at screening (ie, has 1 or 2 copies of ApoE4).
- •15. In the opinion of the investigator, the subject and caregiver will be compliant and have a high probability of completing the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 860
排除标准
- •1) Significant neurologic disease, other than AD, that may affect cognition.
- •2) History of or screening visit brain MRI scan indicative of any other significant abnormality, including but not limited to multiple microhemorrhages (two or more), evidence of a single prior hemorrhage >1 cm3, multiple lacunar infarcts or evidence of a single prior infarct >1 cm3, evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or space-occupying lesions (eg, arachnoid cysts or brain tumors, such as meningioma).
- •NOTE : the screening MRI scan shall be interpreted by the local and central radiologists prior to enrolling the subject. Both local and central interpretations shall be reviewed by the investigator for determination of subject eligibility relative to inclusion criteria # 7 and exclusion criteria # 2.
- •3) Current presence of a clinically important major psychiatric disorder (eg, major depressive disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) or symptom (eg, hallucinations, suicidal ideation/behaviour) that could affect the subject’s ability to complete the study or is a safety concern.
- •4) Current clinically important systemic illness that is likely to result in deterioration of the subject’s condition or affect the subject’s safety during the study.
- •5) History of clinically evident stroke or history of clinically important carotid or vertebrobasilar stenosis or plaque.
- •6) History of seizures, excluding febrile seizures in childhood.
- •7) Weight greater than 120 kg (264 lb).
- •8) History or evidence of any clinically important autoimmune disease or disorder of the immune system (eg, Crohn disease, rheumatoid arthritis).
- •9) Clinically important infection within the last 30 days (eg, chronic persistent or acute infection, such as bronchitis or urinary tract infection [UTI]).
- •10) Treatment with immunosuppressive medications (eg, systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years.
- •11) Myocardial infarction within the last 2 years.
- •12) History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma, and squamous cell carcinoma of the skin.
- •13) Uncontrolled hypertension within 6 months prior to screening.
- •14) Other clinically important abnormality on vital signs, physical examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (eg, atrial fibrillation) that could compromise the study or be detrimental to the subject.
- •15) Hemoglobin level less than 11 g/dL.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza.MedDRA version: 14.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2009-012367-34-BGBioCryst Pharmaceuticals, Inc.600
招募中
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-NOCelgene International II Sàrl485
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's DiseaseEUCTR2018-004614-18-HUEli Lilly and Company1,150
进行中（未招募）
1 期
The study of an investigational drug, Cenicriviroc, for the treatment of liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH).iver fibrosis in Subjects with Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-004566-26-BETobira Therapeutics Inc., a subsidiary of Allergan plc2,000
进行中（未招募）
1 期
A Phase 3 Study in Moderate to Severe Chronic Psoriasis PatientsMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858Plaque PsoriasisEUCTR2014-003492-36-BGCB Biopharma, SPR561